A therapy individualized to each patient’s cancer has produced encouraging three-year data – though talk of accelerated approval remains a moot point.
Confidence in Moderna and Merck & Co.'s novel individualized neoantigen therapy (INT) combination with Keytruda has grown after the companies unveiled new three-year data in melanoma patients.
The candidate mRNA-4157 (V940) is a potential first-in-class INT which is important for Merck as it looks to extend its...
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
